BioCryst Pharmaceuticals
Income Statement
Last updated:
Income statement is a financial statement that shows how profitable a business was over a given reporting period presenting its revenue, expenses or net income. BioCryst Pharmaceuticals's past years’ income statements indicate that its last revenue has increased compared to the previous period by 22% to $331,412,000. The net income raised on -$226,539,000 and profit margin reached -68%. Total operating expenses were $430,460,000.
Profit Margin
| 2014 | 13.60M | -45.18M | -332.08% |
|---|---|---|---|
| 2015 | 48.25M | -43.01M | -89.15% |
| 2016 | 26.35M | -55.14M | -209.25% |
| 2017 | 25.18M | -65.78M | -261.18% |
| 2018 | 20.65M | -101.25M | -490.25% |
| 2019 | 48.83M | -120.06M | -245.86% |
| 2020 | 17.81M | -196.56M | -1103.57% |
| 2021 | 157.17M | -184.06M | -117.11% |
| 2022 | 270.82M | -247.11M | -91.25% |
| 2023 | 331.41M | -226.53M | -68.36% |
BCRX Income Statement (2014 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Revenue | 331.41M | 270.82M | 157.17M | 17.81M | 48.83M | 20.65M | 25.18M | 26.35M | 48.25M | 13.60M |
Cost of revenue | 4.66M | 6.59M | 7.26M | 1.67M | 4.10M | 471K | 1.70M | 2.69M | 1.89M | 122K |
Gross profit | 326.75M | 264.23M | 149.90M | 16.13M | 44.73M | 20.18M | 23.48M | 23.65M | 46.36M | 13.48M |
Operating exp. | ||||||||||
Research and development | 216.56M | 253.29M | 208.80M | 122.96M | 107.06M | 84.88M | 66.96M | 61.00M | 72.75M | 51.79M |
Selling and marketing | 14.40M | 14.89M | 5.70M | 6.56M | 0 | 0 | 0 | 0 | 0 | 0 |
Total operating expenses | 430.46M | 412.66M | 327.62M | 190.89M | 144.18M | 114.40M | 80.89M | 72.26M | 85.80M | 59.25M |
Operating income | -103.70M | -148.43M | -177.72M | -174.75M | -99.45M | -94.22M | -57.41M | -48.60M | -39.44M | -45.77M |
Other income (expenses), net | -122.52M | -95.94M | -4.08M | -8.05M | -9.44M | -108K | -8.37M | -843K | -3.57M | 582K |
Income before tax | -226.22M | -244.38M | -181.80M | -182.81M | -108.89M | -101.25M | -65.78M | -55.14M | -43.01M | -45.18M |
Income tax expense | 310K | 2.73M | 2.25M | 13.75M | 11.16M | 2.14M | 7.86M | 6.00M | 5.02M | 4.82M |
Net income | -226.53M | -247.11M | -184.06M | -196.56M | -120.06M | -101.25M | -65.78M | -55.14M | -43.01M | -45.18M |
Earnings per share | ||||||||||
Basic EPS | -1.18 | -1.33 | -1.03 | -1.18 | -1.04 | -0.98 | -0.78 | -0.75 | -0.59 | -0.68 |
Diluted EPS | -1.18 | -1.33 | -1.03 | -1.18 | -1.04 | -0.98 | -0.78 | -0.75 | -0.59 | -0.68 |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source | Data source |